Q3 2026 Results



• Sanofi achieved another strong quarter with both robust commercial and financial performance. We have also made progress towards defining our roadmap for the future.
We have confirmed our commitment to three focus areas: Immunology, Rare diseases, and Vaccines, and are focused on rebuilding the pipeline through business development, mergers and acquisitions and improving R&D productivity. •

Belén Garijo
Chief Executive Officer

Q3 2026 Company Sales

€14.4 bn

+14.3% at constant exchange rates
+16.2% on a reported basis

Q3 2026 Business Earnings Per Share

€3.55

+19.6% at constant exchange rates
+22% on a reported basis

Sales by Category

Dupixent	Pharma Launches	Vaccines	Other Medicines
€5.7 bn	**€1.4 bn**	**€3.2 bn**	**€4.1 bn**

sanofi

Q3 2026 Results

Sales by Geography

US	Europe	Rest of the World
€8.6 bn	**€2.6 bn**	**€3.3 bn**

Pipeline Progress

- **2 regulatory approvals** in rare diseases, and vaccines
- **1 regulatory submission acceptance** in diabetes
- **2 regulatory designations** in China (priority review), and Europe (PRIME)

For further information on Q3 2026 results and definitions of financial indicators, please refer to the press release issued on October 30, 2026 at: www.sanofi.com/en/investors

sanofi